Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up - Should You Buy?

Key Points

• Maze Therapeutics shares surged 24%, opening at $24.52 versus a prior close of $22.39 and later trading near $27.89.
• Analyst sentiment remains broadly positive, with a consensus “Buy” rating and a $66 average price target, although ratings include both strong-buy and sell calls.
• Insiders sold 191,459 shares worth approximately $5.3 million over the past three months, while major institutional investors—including Frazier Life Sciences, BlackRock and ARCH Venture Management—built or initiated positions.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $22.39, but opened at $24.52. Maze Therapeutics shares last traded at $27.8850, with a volume of 615,856 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on MAZE shares. Wall Street Zen lowered Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. BTIG Research reissued a "buy" rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, August 12th. TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $66.00.

Maze Therapeutics Stock Up 24.0%

The firm has a 50 day moving average price of $27.24 and a 200-day moving average price of $29.42. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -10.96 and a beta of 2.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.76). As a group, equities analysts predict that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Insider Transactions at Maze Therapeutics

In related news, CEO Jason Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total transaction of $907,031.29. Following the completion of the sale, the chief executive officer directly owned 18,151 shares of the company's stock, valued at $477,189.79. The trade was a 65.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the transaction, the chief marketing officer directly owned 16,142 shares in the company, valued at $445,680.62. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 191,459 shares of company stock worth $5,263,539 in the last three months. Insiders own 5.30% of the company's stock.

Institutional Investors Weigh In On Maze Therapeutics

Several large investors have recently bought and sold shares of MAZE. Frazier Life Sciences Management L.P. boosted its position in shares of Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company's stock worth $150,182,000 after purchasing an additional 465,641 shares in the last quarter. TRV GP IV LLC acquired a new stake in Maze Therapeutics during the 2nd quarter worth $133,502,907. ARCH Venture Management LLC acquired a new stake in Maze Therapeutics during the 2nd quarter worth $122,983,582. BlackRock Inc. bought a new position in Maze Therapeutics during the second quarter worth about $104,525,000. Finally, Jupiter Topco LLC bought a new position in Maze Therapeutics during the second quarter worth about $101,764,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze's lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.